Triglyceride accumulation

Triglyceride accumulation is a biological process involving the sequestration of triacylglycerols within intracellular lipid droplets. While this process is physiologically essential in adipocytes for energy homeostasis, ectopic accumulation in non-adipose tissues—such as the liver, skeletal muscle, and heart—is a pathological hallmark of metabolic dysfunction (Source: StatPearls, NIH). It occurs when the rate of fatty acid uptake and de novo lipogenesis exceeds the rate of fatty acid oxidation and export via very-low-density lipoproteins (VLDL) (Source: PubMed, Journal of Biological Chemistry). This accumulation is the defining characteristic of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD. Clinically, excessive triglyceride accumulation is linked to insulin resistance, lipotoxicity, and an increased risk of cardiovascular disease (Source: NIH, Lancet). Because it is a phenotypic outcome rather than a single molecular entity, it is not targeted directly by a single drug-binding event. Instead, therapeutic interventions focus on modulating the enzymes, transporters, and transcription factors—such as DGAT2, PPAR-alpha, and THR-beta—that regulate the underlying lipid metabolic pathways (Source: Nature Reviews Drug Discovery). Monitoring changes in accumulation via imaging techniques like MRI-PDFF or biochemical assays is vital for evaluating the efficacy of metabolic and lipid-lowering therapies (Source: AASLD).

Other names

Lipid accumulationIntracellular lipid buildupSteatosisHepatic steatosisTriacylglycerol accumulationFatty infiltration

Reduction of accumulation via activation of peroxisome proliferator-activated receptor alpha (PPAR-alpha), inhibition of diacylglycerol O-acyltransferase (DGAT), or antisense inhibition of Apolipoprotein C-III (APOC3) to enhance lipid clearance and decrease synthesis (Source: PubMed, FDA).